Spectral AI Secures $31.7M Non-Dilutive BARDA Funding for DeepView® System, Nearing FDA Clearance
summarizeSummary
Spectral AI has been awarded $31.7 million in non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA). This significant capital injection, which is nearly 86% of the company's current market capitalization, is earmarked to accelerate the development of its DeepView® System, an AI-driven burn wound imaging technology, and support its crucial FDA clearance for commercial marketing and distribution. This award is an addition to an existing BARDA contract, bringing the total committed funding to over $86 million, with a potential value up to $150 million. The non-dilutive nature of this funding is highly positive, as it provides substantial capital without impacting shareholder equity. This development significantly de-risks the company's path to market for its core product and provides a strong validation of the DeepView System's potential. Investors will now closely watch for updates on the FDA clearance process and further milestones in the system's development.
At the time of this announcement, MDAI was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.8M. The 52-week trading range was $1.04 to $3.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.